ANTEOTECH LTD — Capital/Financing Update 2015

Mar 31, 2015

1 April 2015

==> picture [276 x 85] intentionally omitted <==

ANTEO TECHNOLOGIES SIGNS NEW AGREEMENT WITH LARGE GLOBAL HEALTHCARE COMPANY ‘POC1’

• New agreement signed following completion of 18 month Feasibility Study with POC1

• Continuing partnership with POC1 a strong endorsement of the Mix&Go™technology

• New agreement expands program and delivers ongoing revenue

• Further announcements on commercial agreements and non-core opportunities pending

Today, Anteo Technologies Pty Ltd, a wholly owned subsidiary of Anteo Diagnostics Limited (ASX: ADO) is pleased to announce a new agreement that expands its research and development program with a large global healthcare company, referred to as POC1 for confidentiality reasons.

The new agreement is an extension and broadening of the initial Feasibility Study between Anteo and POC1 entered into in June 2013. The success of the initial study is the catalyst for this agreement.

POC1 is developing a handheld immunoassay analyser, a point-of-care device, to better diagnose health conditions in a more timely manner.

Anteo Technologies Pty Ltd. has been exploring the use of Anteo’s proprietary Mix&Go™ technology to precisely attach functional antibodies to different surfaces. Anteo recently developed novel reagents that have proven effective on a variety of surfaces; these novel applications and all associated intellectual property have been captured in Anteo’s recent patent applications[[i]] . Anteo has now entered into a new agreement with POC1 under which Anteo will use its new intellectual property to improve the performance characteristics and precisely attach functional antibodies to POC1’s sensor surface. Anteo recently concluded a previous agreement with POC1 under which Anteo used Mix&Go™ technology to successfully attach antibodies to POC1’s beads.

Dr Geoff Cumming, CEO, Anteo Technologies said the research conducted on beads to date has delivered positive results that satisfy the requirements of POC1.

“This agreement is a very positive development for Anteo and it is a strong endorsement of the Mix&Go™technology – Anteo’s patented and wholly owned technology platform. POC1 is a wellrecognised and established global healthcare company and this recognition and confidence in the diverse applicability of Mix&Go is pleasing. The POC1 global healthcare company is fully funding the next phase, which further demonstrates its commitment and confidence.”

This agreement is milestone-based and Anteo’s executive team is confident the milestones are realistic and achievable.

Dr Joe Maeji, Chief Scientific Officer, Anteo Technologies said: “We have a dedicated and highly skilled team of scientists who have been working on this project since 2013. This continuity and expertise enhances our work and has established a foundation for success. It is exciting that we now have the opportunity to view the device holistically, which we anticipate will lead to improved outcomes and help POC1 achieve its design goals.”

Anteo Technologies aims to see this important commercialisation opportunity to completion. In addition to recent patent filings, Anteo has put in place the necessary facilities, infrastructure and expertise to support POC1’s development plans and ensure project success. This includes the construction of a brand new clean lab fit-out with temperature and humidity control, and the installation of a new sciFLEXARRAYER S5 by Scienion.

==> picture [115 x 87] intentionally omitted <==

==> picture [268 x 55] intentionally omitted <==

==> picture [276 x 85] intentionally omitted <==

Dr Geoff Cumming said: “From a commercial perspective, these collaborative agreements also make small but meaningful revenue contributions to Anteo. These are important revenue streams for Anteo and help the company preserve its strong cash position,”

“This agreement is a milestone in itself and could well enable us to identify additional licensing opportunities down the track,”

“In addition, we are pleased to confirm that Anteo is pursuing other commercial agreements, as well as non-core opportunities that demonstrate the broader potential applications for Mix&Go. We look forward to updating shareholders in the near term.”

Anteo Technologies Pty Ltd

www.anteotech.com

Anteo uses its patented technology to develop, manufacture and commercialise proprietary surface coatings for use in healthcare, life sciences and beyond. Its patented technology is applied in the Mix&Go product range, which delivers solutions to the challenges of establishing highly functional interfaces between fragile biomolecules, and synthetic, and often incompatible materials.

==> picture [596 x 138] intentionally omitted <==

[i] Patent announcement 24/02/15 and Patent announcement 25/08/14